The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• only DOD beneficiaries
• adult patients 18 years of age or older
• adult patients with proptosis, ocular/orbital pain, diplopia, lid/orbital edema, or lid/orbital erythema associated with autoimmune thyroid disease
Locations
United States
Maryland
Walter Reed National Military Medical Center
RECRUITING
Bethesda
Contact Information
Primary
THANH D HOANG, DO
thanh.d.hoang.mil@health.mil
3012955165
Backup
Iris Morris, PhD
iris.e.morris3.civ@health.mil
3013194599
Time Frame
Start Date: 2021-05-12
Estimated Completion Date: 2027-12-12
Participants
Target number of participants: 100
Related Therapeutic Areas
Sponsors
Leads: Walter Reed National Military Medical Center